Skip to main content
v2026.11,986 entries · CC-BY 4.0
CASRAIAsk CASRAI · AI assistant for researchAsk a research question. Answers come with their sources.Funder rules, compliance, methods and publishing. Answers link the sources they rest on.

Editorial · CASRAI · AI and ML research outputs

Orakl Oncology raises $34 million for AI drug research

Orakl Oncology has raised $34 million to expand AI drug research, laboratory data generation and work with patient-derived cancer models.

Published 16 Nov 2026· 4 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

Paris-based Orakl Oncology announced a $34 million Series A on 12 November 2026 to expand its AI drug-research platform, according to co-lead investor Norrsken VC. The financing backs laboratory data generation and predictive modelling, with implications for cancer researchers and hospitals contributing the patient samples and clinical records behind the technology.

What the financing supports

Norrsken and Singular co-led the round, bringing total funding to $50 million. Participants include InfraVia, Serena, the Patient Autonome Fund managed by Bpifrance, teampact.ventures and Plug and Play, alongside returning investors Verve Ventures, Speedinvest and HCVC. The Next Web independently reported the $34 million financing and the two lead investors.

The central research proposition is to make decisions about drug development using experiments on patient-derived material alongside computational predictions. The investment therefore funds a business built around generating biological evidence, rather than simply processing an existing collection of documents or trial records.

How the platform connects laboratory models and AI

On its company website, Orakl describes growing tumour organoids from patients, screening their responses to drugs, and combining the results with genomic, transcriptomic and phenotypic information. The experimental observations are linked to longitudinal clinical histories. An organoid is the laboratory model in this system; the software works with the biological measurements and associated patient information.

Orakl describes two current offerings: O-Predict, intended to support clinical-trial decisions, and O-Target, aimed at identifying therapeutic targets. These are descriptions of the company’s research products and objectives. They do not establish that a particular medicine works or that a model can choose treatment for an individual patient.

The company also says its hospital alliances develop patient-matched datasets and living biological samples for drug development and academic research. This makes the underlying biobank and its associated records central to the research, alongside the prediction algorithms.

The research evidence has a defined scope

The SCOPE preprint, version two posted on 18 April 2026, evaluates trial-level predictions against 32 treatment arms from 23 published colorectal and pancreatic cancer trials. Its authors report correctly ranking treatments in seven of eight head-to-head comparisons. The paper is a preprint, without peer-review certification.

The authors describe modest samples and a validation set dominated by chemotherapy. They also state that external validation of predictions for individual patients is ongoing and will be reported separately. For researchers assessing internal and external validation, the distinction is consequential: agreement with results for trial groups does not establish performance for every patient or another cancer type.

European Biotechnology’s reporting similarly distinguishes the retrospective evidence from the independent, prospective studies needed to demonstrate broader performance. The Next Web also highlights uncertainty about how the model handles newer drugs. These assessments make validation a substantive next step alongside commercial expansion.

From an institute spin-out to a larger research business

Orakl identifies itself as a Gustave Roussy spin-off. Its earlier financing provides context for the new round: Tech.eu reported an €11 million seed round on 3 December 2024, led by Singular, to support growth and the launch of products then named O-Predict and O-Validate.

At that stage, Tech.eu also reported plans to use the platform to inform in-licensing decisions and build an internal pipeline. The company’s development story therefore includes selecting drug programmes as well as selling predictive tools. For institutional partners, that history adds a commercialisation dimension to the laboratory collaboration: the possible uses of the research extend beyond producing a model or an academic paper.

In that 2024 report, Gustave Roussy general director Fabrice Barlesi welcomed the institute’s spin-out and its work on patient-derived models. Singular partner Jeremy Uzan emphasised the combination of cancer research, cell biology and computational biology expertise. Those historical comments describe the institutional and scientific foundation of the business; they are not new endorsements of the November financing or independent validation of its predictions.

What this means for research institutions

The SCOPE authors say their patient material and data came from ethics-approved Gustave Roussy protocols with written consent. Patient-level clinical and screening data are not public; access requests are considered individually under institutional and contractual agreements.

For university and hospital research offices, the practical implication is that collaboration involves both biological material and data rights. A data sharing agreement, permission to reuse records and access to underlying measurements are substantive research questions. A financing announcement does not resolve them. Equally, a proprietary dataset supporting academic research should not be read as a publicly downloadable research resource.

What happens next

Norrsken says the funding will support fivefold growth in data generation, expansion from colorectal and pancreatic cancers into lung and gastric cancers, and new US and UK teams. The plan includes predictions across more than ten drug programmes and work on identifying and validating drug co-targets. These are funded ambitions, with no completion date specified in the announcement. Their research value will depend on the evidence produced as the platform expands.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →